

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (currently amended) A method for inhibiting VEGF-induced vascular endothelial growth factor (VEGF)-induced cell proliferation in a subject in need thereof, comprising, administering to said subject an effective amount of oxidized adenosine triphosphate (o-ATP).

2. (previously presented) The method according to claim 1, wherein the subject has and is treated for a disease involving VEGF-induced cell proliferation.

3. (previously presented) The method according to claim 1, wherein the subject has and is treated for cancer.

4. (previously presented) The method according to claim 3, wherein the cancer is selected from the group consisting of lymphoma and leukemia.

5. (currently amended) A preparation composition comprising oxidized adenosine triphosphate (o-ATP) in combination with a substance selected from the group consisting of cytotoxic compounds, cytostatic compounds, antimetabolites, alkaloids, antibiotics, alkylating agents, peptides, biological response modulators and cytokines.

6. (currently amended) A preparation composition comprising oxidized adenosine triphosphate (o-ATP) in combination with a substance selected from the group consisting of lipid lowering drugs and statins.

7. (currently amended) The preparation composition according to claim 5, wherein the preparation is in a form selected from the group consisting of tablet, pill, capsule, granulate, powder, suppository, solution, spray, syrup, cream, ointment, gel, paste, lotion, emulsion and suspension.

8. (currently amended) The preparation composition according to claim 6, wherein the preparation is in a form selected from the group consisting of tablet, pill, capsule, granulate, powder, suppository, solution, spray, syrup, cream, ointment, gel, paste, lotion, emulsion and suspension.

9. (currently amended) A method for inhibiting VEGF-induced vascular endothelial growth factor (VEGF)-induced cell proliferation of endothelial cells, comprising: administering to said endothelial cells an effective amount of oxidized adenosine triphosphate (o-ATP).

10. (previously presented) The method according to claim 9, wherein the endothelial cells are human endothelial cells.

11. (previously presented) The method according to claim 10, wherein the endothelial cells are human umbilical vein endothelial cells.

12. (previously presented) The method according to claim 9, wherein the cells are human endothelial cells of a subject.

13. (previously presented) The method according to claim 12, wherein the o-ATP is administered to said subject in a daily dosage of 0.01 to 100 mg per kg of body weight of said patient.

14. (previously presented) The method according to claim 12, wherein the o-ATP is administered in the form of a preparation selected from the group consisting of tablet, pill, capsule, granulate, powder, suppository, solution, spray, syrup, cream, ointment, gel, paste, lotion, emulsion and suspension.

15. (currently amended) The method according to claim [[15]] 1, wherein the o-ATP is administered in a daily dosage of 0.01 to 100 mg per kg of body weight of said patient.

16. (new) A method for inhibiting VEGF-induced cell proliferation of human endothelial cells, comprising administering to said cells an effective amount of periodate oxidized adenosine triphosphate.

17. (new) The method according to claim 16, wherein the o-ATP is administered in a daily dosage of 0.01 to 100 mg per kg of body weight of said patient.